{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:38:08Z","timestamp":1793813888231,"version":"4.6.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,5,18]],"date-time":"2013-05-18T00:00:00Z","timestamp":1368835200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s00296-013-2772-6","type":"journal-article","created":{"date-parts":[[2013,5,17]],"date-time":"2013-05-17T05:26:25Z","timestamp":1368768385000},"page":"2199-2213","source":"Crossref","is-referenced-by-count":79,"title":["Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis"],"prefix":"10.1007","volume":"33","author":[{"given":"Marina Amaral de \u00c1vila","family":"Machado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Michel","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra Maciel","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e2nia Eloisa","family":"de Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Maria","family":"Kakehasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli Iola Gurgel","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela Leal","family":"Cherchiglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco de Assis","family":"Acurcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,18]]},"reference":[{"key":"2772_CR1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369:1379\u20131390","journal-title":"Lancet"},{"key":"2772_CR2","doi-asserted-by":"crossref","unstructured":"Gensler L (2011) Clinical features of ankylosing spondylitis. In: Hochberg MC, Silman AJ, Smolen JS et al (eds) Rheumatology (5th edn), pp 9\u201314","DOI":"10.1016\/B978-0-323-06551-1.00112-3"},{"key":"2772_CR3","doi-asserted-by":"crossref","unstructured":"Rudwaleit M (2011) Classification and epidemiology of spondyloarthrits. In: Hochberg MC, Silman AJ, Smolen JS et al (eds) Rheumatology (5th edn), pp 3\u20138","DOI":"10.1016\/B978-0-323-06551-1.00111-1"},{"key":"2772_CR4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ard.60.4.353","volume":"60","author":"A Boonen","year":"2001","unstructured":"Boonen A, Chorus A, Miedema H, Van Der Heijde D, Van Der Tempel H, Van Der Linden S (2001) Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 60:353\u2013358. doi: 10.1136\/ard.60.4.353","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2772_CR5","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ncprheum0297","volume":"2","author":"A Boonen","year":"2006","unstructured":"Boonen A (2006) A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. Nat Clin Pract Rheumatol 2(10):546\u2013553. doi: 10.1038\/ncprheum0297","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2772_CR6","doi-asserted-by":"crossref","unstructured":"Sieper J (2011) Management of ankylosing spondylitis. In: Hochberg MC, Silman AJ, Smolen JS et al (eds) Rheumatology (5th edn), pp 37\u201357","DOI":"10.1016\/B978-0-323-06551-1.00116-0"},{"key":"2772_CR7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X et al (2011) 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70:896\u2013904. doi: 10.1136\/ard.2011.151027","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2772_CR8","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/rheumatology\/keq078","volume":"49","author":"C Escalas","year":"2010","unstructured":"Escalas C, Trijau S, Dougados M (2010) Evaluation of the treatment effect of NSAIDs\/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. Rheumatology (Oxford) 49(7):1317\u20131325. doi: 10.1093\/rheumatology\/keq078","journal-title":"Rheumatology (Oxford)"},{"key":"2772_CR9","unstructured":"Green S, Higgins JPT, Alderson P et al (2011). In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The cochrane collaboration. Available from www.cochrane-handbook.org"},{"key":"2772_CR10","doi-asserted-by":"crossref","unstructured":"Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7). doi: 10.1136\/bmj.b2700","DOI":"10.1136\/bmj.b2700"},{"key":"2772_CR11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden Van der","year":"1984","unstructured":"Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27:361\u2013368. doi: 10.1002\/art.1780270401","journal-title":"Arthritis Rheum"},{"key":"2772_CR12","volume-title":"Rheumatology","author":"J Sieper","year":"2011","unstructured":"Sieper J (2011) Management of ankylosing spondylitis. Section\u00a09 Spondyloarthropathies. In: Hochberg MC (ed) Rheumatology, 5th edn. Philadelphia, Elsevier","edition":"5"},{"key":"2772_CR13","doi-asserted-by":"crossref","unstructured":"Woodroffe R, Yao GL, Meads C et al (2005) Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess 9(21)","DOI":"10.3310\/hta9210"},{"key":"2772_CR14","unstructured":"Higgins JPT, Altman DG, Sterne JAC (2011) Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The cochrane collaboration. Available from www.cochrane-handbook.org"},{"issue":"1","key":"2772_CR15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159\u2013174","journal-title":"Biometrics"},{"key":"2772_CR16","unstructured":"Deeks JJ, Higgins JPT, Altman DG (2011) Chapter 9: analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The cochrane collaboration. Available from www.cochrane-handbook.org"},{"key":"2772_CR17","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-ytter Y, Sch\u00fcnemann HJ (2008) GRADE: what is \u201cquality of evidence\u201d and why is it important to clinicians? BMJ 336:995\u2013998. doi: 10.1136\/bmj.39490.551019.BE","journal-title":"BMJ"},{"key":"2772_CR18","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: going from evidence to recommendations. BMJ 336:1049\u20131051. doi: 10.1136\/bmj.39493.646875.AE","journal-title":"BMJ"},{"issue":"7","key":"2772_CR19","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136\u20132146","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2772_CR20","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/art.22887","volume":"57","author":"JC Davis Jr","year":"2007","unstructured":"Davis JC Jr, Revicki D, van der Heijde DM et al (2007) Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum 57(6):1050\u20131057. doi: 10.1002\/art.21913","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2772_CR21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.23527","volume":"59","author":"M Dougados","year":"2008","unstructured":"Dougados M, Luo MP, Maksymowych WP et al (2008) Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial. Arthritis Rheum 59(4):553\u2013560. doi: 10.1002\/art.23527","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2772_CR22","first-page":"1346","volume":"35","author":"DA Revicki","year":"2008","unstructured":"Revicki DA, Luo MP, Wordsworth P et al (2008) Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). J Rheumatol 35(7):1346\u20131353 (Epub 2008 May 15). Erratum in: J Rheumatol. 2011 Apr; 38(4):788","journal-title":"J Rheumatol"},{"issue":"6","key":"2772_CR23","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/ard.2007.087270","volume":"68","author":"D Heijde van der","year":"2009","unstructured":"van der Heijde D, Schiff MH, Sieper J et al (2009) Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2\u00a0years: long-term results from the ATLAS trial. Ann Rheum Dis 68(6):922\u2013929. doi: 10.1136\/ard.2007.087270 (Epub 2008 Aug 13)","journal-title":"Ann Rheum Dis"},{"key":"2772_CR24","first-page":"505","volume":"52","author":"WP Maksymowych","year":"2005","unstructured":"Maksymowych WP, Rahman P, Keystone E, Wong R, Inman R (2005) Efficacy of adalimumab in active ankylosing spondylitis (AS)\u2014results of the Canadian AS study. Arthritis Rheum 52:505","journal-title":"Arthritis Rheum"},{"issue":"12","key":"2772_CR25","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1002\/art.23044","volume":"56","author":"RG Lambert","year":"2007","unstructured":"Lambert RG, Salonen D, Rahman P et al (2007) Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 56(12):4005\u20134014. doi: 10.1002\/art.23044","journal-title":"Arthritis Rheum"},{"issue":"18","key":"2772_CR26","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","volume":"346","author":"JD Gorman","year":"2002","unstructured":"Gorman JD, Sack KE, Davis JC Jr (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346(18):1349\u20131356","journal-title":"N Engl J Med"},{"issue":"11","key":"2772_CR27","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, van der Heijde D, Braun J et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis. Arthritis Rheum 48(11):3230\u20133236. doi: 10.1002\/art.11325","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2772_CR28","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","volume":"48","author":"J Brandt","year":"2003","unstructured":"Brandt J, Khariouzov A, Listing J et al (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48(6):1667\u20131675. doi: 10.1002\/art.11017","journal-title":"Arthritis Rheum"},{"issue":"12","key":"2772_CR29","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","volume":"63","author":"A Calin","year":"2004","unstructured":"Calin A, Dijkmans BA, Emery P et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63(12):1594\u20131600. doi: 10.1136\/ard.2004.020875","journal-title":"Ann Rheum Dis"},{"key":"2772_CR30","doi-asserted-by":"crossref","unstructured":"van der Heijde D, Da Silva JC, Dougados M et al (2006) Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 65(12):1572\u20131577. doi: 10.1136\/ard.2006.056747","DOI":"10.1136\/ard.2006.056747"},{"issue":"6","key":"2772_CR31","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kem069","volume":"46","author":"J Braun","year":"2007","unstructured":"Braun J, McHugh N, Singh A, Wajdula JS, Sato R (2007) Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50\u00a0mg once-weekly and 25\u00a0mg twice-weekly. Rheumatology (Oxford) 46(6):999\u20131004. doi: 10.1093\/rheumatology\/kem069","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"2772_CR32","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1136\/ard.2009.121327","volume":"69","author":"N Barkham","year":"2010","unstructured":"Barkham N, Coates LC, Keen H et al (2010) Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 69(11):1926\u20131928. doi: 10.1136\/ard.2009.121327 Erratum in: Ann Rheum Dis. 2011 Aug; 70(8):1519","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2772_CR33","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/ard.2010.139261","volume":"70","author":"M Dougados","year":"2011","unstructured":"Dougados M, Braun J, Szanto S et al (2011) Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis 70(5):799\u2013804. doi: 10.1136\/ard.2010.139261 . (Erratum in: Ann Rheum Dis. 2011 Jul; 70(7):1349)","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2772_CR34","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","volume":"63","author":"J Braun","year":"2011","unstructured":"Braun J, van der Horst-Bruinsma IE, Huang F et al (2011) Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 63(6):1543\u20131551. doi: 10.1002\/art.30223","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2772_CR35","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3899\/jrheum.110885","volume":"39","author":"J Braun","year":"2012","unstructured":"Braun J, Pavelka K, Ramos-Remus C et al (2012) Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. J Rheumatol 39(4):836\u2013840. doi: 10.1002\/art.30223 (Epub 2012 Feb 15)","journal-title":"J Rheumatol"},{"issue":"9313","key":"2772_CR36","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313):1187\u20131193. doi: 10.1016\/S0140-6736(02)08215-6","journal-title":"Lancet"},{"issue":"2","key":"2772_CR37","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D Heijde van der","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2):582\u2013591. doi: 10.1002\/art.24001","journal-title":"Arthritis Rheum"},{"key":"2772_CR38","doi-asserted-by":"crossref","unstructured":"van der Heijde D, Han C, DeVlam K et al (2006) Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum 55(4):569\u2013574. doi: 10.1002\/art.22097","DOI":"10.1002\/art.22097"},{"issue":"5","key":"2772_CR39","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/art.21790","volume":"54","author":"J Braun","year":"2006","unstructured":"Braun J, Landew\u00e9 R, Hermann KG et al (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 54(5):1646\u20131652. doi: 10.1002\/art.21790","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2772_CR40","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","volume":"60","author":"N Barkham","year":"2009","unstructured":"Barkham N, Keen HI, Coates LC et al (2009) Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 60(4):946\u2013954. doi: 10.1002\/art.24408 Erratum in: Arthritis Rheum. 2010 Oct; 62(10):3005","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2772_CR41","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3899\/jrheum.091042","volume":"37","author":"RD Inman","year":"2010","unstructured":"Inman RD, Maksymowych WP (2010) CANDLE study group. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol 37(6):1203\u20131210. doi: 10.3899\/jrheum.091042 (Epub 2010 Mar 15)","journal-title":"J Rheumatol"},{"issue":"8","key":"2772_CR42","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3899\/jrheum.091043","volume":"37","author":"WP Maksymowych","year":"2010","unstructured":"Maksymowych WP, Salonen D, Inman RD, Rahman P, Lambert RG (2010) CANDLE study group. Low-dose infliximab (3\u00a0mg\/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. J Rheumatol 37(8):1728\u20131734. doi: 10.3899\/jrheum.091043 (Epub 2010 May 1)","journal-title":"J Rheumatol"},{"issue":"11","key":"2772_CR43","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/ard.2004.022582","volume":"64","author":"H Marzo-Ortega","year":"2005","unstructured":"Marzo-Ortega H, McGonagle D, Jarrett S et al (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64(11):1568\u20131575. doi: 10.1136\/ard.2004.022582 (Epub 2005 Apr 13)","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2772_CR44","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC Jr, Heijde Dv et al (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58(11):3402\u20133412","journal-title":"Arthritis Rheum"},{"key":"2772_CR45","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00296-009-1157-3","volume":"30","author":"AR Giardina","year":"2010","unstructured":"Giardina AR, Ferrante A, Ciccia F et al (2010) A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int 30:1437\u20131440. doi: 10.1007\/s00296-009-1157-3 (Epub 2009 Oct 23)","journal-title":"Rheumatol Int"},{"key":"2772_CR46","unstructured":"EU Clinical Trials Register. Prevention of the progression of very early symptoms into ankylosing spondylitis: a placebo controlled trial with etanercept. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2009-015515-40 . Accessed 11 Jan 2013"},{"key":"2772_CR47","unstructured":"EU Clinical Trials Register. Estudio piloto randomizado, doble ciego, multic\u00e9ntrico a 12 semanas para evaluar el efecto de etanercept 100\u00a0mg y 50\u00a0mg semanales en sujetos con espondilitis anquilosante. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2006-002349-35 . Accessed 11 Jan 2013"},{"key":"2772_CR48","unstructured":"EU Clinical Trials Register. A multicentre, double-blind, placebo-controlled, randomised study of etanercept in the treatment of adult patients with active, severe and advanced axial ankylosing spondylitis. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2006-002748-27 . Accessed 11 Jan 2013"},{"key":"2772_CR49","doi-asserted-by":"crossref","unstructured":"McLeod C, Bagust A, Boland A, et al (2007) Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 11(28)","DOI":"10.3310\/hta11280"},{"issue":"5","key":"2772_CR50","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S1699-258X(07)73688-4","volume":"3","author":"J Montilla Salas","year":"2007","unstructured":"Montilla Salas J, Mu\u00f1oz Gom\u00e1riz E, Collantes E (2007) Meta-analysis of efficacy of anti-TNF alpha therapy in ankylosing spondylitis patients. Reumatol Clin 3(5):204\u2013212. doi: 10.1016\/S1699-258X(07)73688-4 (Epub 2008 Dec 29)","journal-title":"Reumatol Clin"},{"issue":"10","key":"2772_CR51","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1136\/ard.2008.098822","volume":"69","author":"A Fouque-Aubert","year":"2010","unstructured":"Fouque-Aubert A, Jette-Paulin L, Combescure C, Basch A, Tebib J, Gossec L (2010) Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis 69(10):1756\u20131761. doi: 10.1136\/ard.2008.098822 (Epub 2009 Jul 28)","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2772_CR52","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/rheumatology\/kes026","volume":"51","author":"X Baraliakos","year":"2012","unstructured":"Baraliakos X, van den Berg R, Braun J, van der Heijde D (2012) Update of the literature review on treatment with biologics as a basis for the first update of the ASAS\/EULAR management recommendations of ankylosing spondylitis. Rheumatology (Oxford) 51(8):1378\u20131387","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"2772_CR53","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.medcli.2010.11.032","volume":"137","author":"MJ P\u00e9rez-Sola","year":"2011","unstructured":"P\u00e9rez-Sola MJ, Torre-Cisneros J, P\u00e9rez-Zafrilla B et al (2011) Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. Med Clin (Barc). 137(12):533\u2013540. doi: 10.1016\/j.medcli.2010.11.032 (Epub 2011 Apr 22)","journal-title":"Med Clin (Barc)."},{"issue":"5","key":"2772_CR54","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","volume":"57","author":"JJ G\u00f3mez-Reino","year":"2007","unstructured":"G\u00f3mez-Reino JJ, Carmona L, Descalzo MA (2007) Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57(5):756\u2013761. doi: 10.1002\/art.22768","journal-title":"Arthritis Rheum"},{"key":"2772_CR55","doi-asserted-by":"crossref","unstructured":"Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev, Issue 2. Art. No.: CD008794. doi: 10.1002\/14651858.CD008794.pub2","DOI":"10.1002\/14651858.CD008794.pub2"},{"issue":"3","key":"2772_CR56","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3111\/13696998.2012.660255","volume":"15","author":"A Migliore","year":"2012","unstructured":"Migliore A, Broccoli S, Bizzi E, Lagan\u00e0 B (2012) Indirect comparison of the effects of anti-TNF biological agents in patients with ankylosing spondylitis by means of a mixed treatment comparison performed on efficacy data from published randomised, controlled trials. J Med Econ 15(3):473\u2013480. doi: 10(3111\/13696998).2012.660255 (Epub 2012 Feb 16)","journal-title":"J Med Econ"},{"issue":"9","key":"2772_CR57","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/rheumatology\/ken207","volume":"47","author":"EK Li","year":"2008","unstructured":"Li EK, Griffith JF, Lee VW et al (2008) Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology (Oxford) 47(9):1358\u20131363. doi: 10.1093\/rheumatology\/ken207 (Epub 2008 Jun 23). Erratum in: Rheumatology (Oxford). 2010 Jul; 49(7):1423","journal-title":"Rheumatology (Oxford)"},{"key":"2772_CR58","doi-asserted-by":"crossref","unstructured":"Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2006, Issue 4. Art. No.: CD004524. doi: 10.1002\/14651858.CD004524.pub3","DOI":"10.1002\/14651858.CD004524.pub3"},{"issue":"4","key":"2772_CR59","first-page":"722","volume":"33","author":"J Chen","year":"2006","unstructured":"Chen J, Liu C (2006) Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol 33(4):722\u2013731","journal-title":"J Rheumatol"},{"issue":"6","key":"2772_CR60","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1371\/journal.pmed.0040184","volume":"4","author":"L Bero","year":"2007","unstructured":"Bero L, Oostvogel F, Bacchetti P, Lee K (2007) Factors associated with findings of published trials of drug\u2013drug comparisons: why some statins appear more efficacious than others. PLoS Med. 4(6):e184. doi: 10.1371\/journal.pmed.0040184","journal-title":"PLoS Med."},{"key":"2772_CR61","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","volume":"326","author":"J Lexchin","year":"2003","unstructured":"Lexchin J, Bero LA, Djulbegovic B, Clark O (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326:1167. doi: 10.1136\/bmj.326.7400.1167","journal-title":"BMJ"},{"key":"2772_CR62","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/bmj.325.7358.249","volume":"325","author":"LL Kjaergard","year":"2002","unstructured":"Kjaergard LL, Als-Nielsen B (2002) Association between competing interests and authors\u2019conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ 325:249. doi: 10.1136\/bmj.325.7358.249","journal-title":"BMJ"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-013-2772-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-013-2772-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-013-2772-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T07:21:46Z","timestamp":1559028106000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-013-2772-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,18]]},"references-count":62,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["2772"],"URL":"https:\/\/doi.org\/10.1007\/s00296-013-2772-6","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,18]]}}}